Characteristics of the study population (N = 562)
| Characteristic . | n . | % . |
|---|---|---|
| Sex | ||
| Female | 163 | 29.0 |
| Male | 399 | 71.0 |
| Age, y | ||
| <0.5 | 114 | 20.3 |
| 0.5-1.5 | 146 | 26.0 |
| 1.5-5 | 131 | 23.3 |
| >5 | 171 | 30.4 |
| Graft source | ||
| Bone marrow | 312 | 55.5 |
| Cord blood | 153 | 27.2 |
| Peripheral blood | 97 | 17.3 |
| Donor | ||
| Family | 158 | 28.1 |
| Unrelated | 404 | 71.9 |
| Matching status | ||
| Matched | 317 | 56.4 |
| Mismatched | 192 | 34.2 |
| Unknown | 53 | 9.4 |
| Disease group | ||
| CIDs | 173 | 30.8 |
| SCID | 154 | 27.4 |
| Neutrophil disorders | 134 | 23.8 |
| HLH-related diseases | 101 | 18.0 |
| Serotherapy | ||
| Antithymocyte globulin | 265 | 47.2 |
| Alemtuzumab | 174 | 31.0 |
| No serotherapy | 87 | 15.5 |
| Unknown | 36 | 6.4 |
| Year of transplantation | ||
| <2013 | 184 | 32.7 |
| 2013 | 157 | 27.9 |
| Unknown | 221 | 39.3 |
| GVHD prophylaxis regimen | ||
| Cyclosporine containing | 392 | 69.8 |
| Tacrolimus containing | 42 | 7.5 |
| Other/unknown | 128 | 22.8 |
| Number of alkylators | ||
| 1 alkylator (busulfan) | 393 | 69.9 |
| 2 alkylators | 155 | 27.6 |
| Busulfan and unknown agent | 14 | 2.5 |
| Conditioning regimen | ||
| Busulfan/cyclophosphamide/fludarabine | 127 | 22.6 |
| Busulfan/fludarabine | 392 | 69.8 |
| Busulfan/cyclophosphamide/etoposide | 19 | 3.4 |
| Busulfan/fludarabine/clofarabine | 1 | 0.2 |
| Busulfan/fludarabine/thiotepa | 4 | 0.7 |
| Busulfan/fludarabine/melphalan | 4 | 0.7 |
| Busulfan/thiotepa | 1 | 0.2 |
| Busulfan/missing | 14 | 2.5 |
| Characteristic . | n . | % . |
|---|---|---|
| Sex | ||
| Female | 163 | 29.0 |
| Male | 399 | 71.0 |
| Age, y | ||
| <0.5 | 114 | 20.3 |
| 0.5-1.5 | 146 | 26.0 |
| 1.5-5 | 131 | 23.3 |
| >5 | 171 | 30.4 |
| Graft source | ||
| Bone marrow | 312 | 55.5 |
| Cord blood | 153 | 27.2 |
| Peripheral blood | 97 | 17.3 |
| Donor | ||
| Family | 158 | 28.1 |
| Unrelated | 404 | 71.9 |
| Matching status | ||
| Matched | 317 | 56.4 |
| Mismatched | 192 | 34.2 |
| Unknown | 53 | 9.4 |
| Disease group | ||
| CIDs | 173 | 30.8 |
| SCID | 154 | 27.4 |
| Neutrophil disorders | 134 | 23.8 |
| HLH-related diseases | 101 | 18.0 |
| Serotherapy | ||
| Antithymocyte globulin | 265 | 47.2 |
| Alemtuzumab | 174 | 31.0 |
| No serotherapy | 87 | 15.5 |
| Unknown | 36 | 6.4 |
| Year of transplantation | ||
| <2013 | 184 | 32.7 |
| 2013 | 157 | 27.9 |
| Unknown | 221 | 39.3 |
| GVHD prophylaxis regimen | ||
| Cyclosporine containing | 392 | 69.8 |
| Tacrolimus containing | 42 | 7.5 |
| Other/unknown | 128 | 22.8 |
| Number of alkylators | ||
| 1 alkylator (busulfan) | 393 | 69.9 |
| 2 alkylators | 155 | 27.6 |
| Busulfan and unknown agent | 14 | 2.5 |
| Conditioning regimen | ||
| Busulfan/cyclophosphamide/fludarabine | 127 | 22.6 |
| Busulfan/fludarabine | 392 | 69.8 |
| Busulfan/cyclophosphamide/etoposide | 19 | 3.4 |
| Busulfan/fludarabine/clofarabine | 1 | 0.2 |
| Busulfan/fludarabine/thiotepa | 4 | 0.7 |
| Busulfan/fludarabine/melphalan | 4 | 0.7 |
| Busulfan/thiotepa | 1 | 0.2 |
| Busulfan/missing | 14 | 2.5 |